Blow Fill Seal specialist Ritedose, which offers CDMO services and produces its own inhalation solutions, has announced that it will spend $17 million to add 10,000 sq ft of laboratory space, tripling its current lab space. In June 2024, the company announced that it was adding BFS capacity to allow for manufacturing of an additional 180 million unit doses of opthalmic and respiratory solutions.
According to Ritedose, the project will happen in two phases: first, a new 10,000 sq ft analytical chemistry lab and then conversion of the existing chemistry lab into a 6,000 sq ft microbiology lab. Both projects should be completed in the first half of 2026, the company said.
Ritedose CEO Jody Chastain commented, “By expanding our cGMP laboratory space, we’re not just meeting our current needs, we’re preparing Ritedose for the future of pharmaceutical development. These investments give us the capacity, flexibility and advanced capabilities to support next-generation therapies, strengthen our regulatory leadership, and ensure we can deliver life-changing treatments to patients with even greater speed and reliability.”
Read the Ritedose press release
